➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Mallinckrodt
Harvard Business School
Merck
Moodys

Last Updated: September 28, 2021

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 208030


Email this page to a colleague

« Back to Dashboard

NDA 208030 describes FERRIPROX, which is a drug marketed by Chiesi and is included in three NDAs. It is available from two suppliers. There are five patents protecting this drug and one Paragraph IV challenge. Additional details are available on the FERRIPROX profile page.

The generic ingredient in FERRIPROX is deferiprone. There are four drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the deferiprone profile page.
Summary for 208030
Tradename:FERRIPROX
Applicant:Chiesi
Ingredient:deferiprone
Patents:2
Formulation / Manufacturing:see details
Pharmacology for NDA: 208030
Mechanism of ActionIron Chelating Activity
Suppliers and Packaging for NDA: 208030
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
FERRIPROX deferiprone SOLUTION;ORAL 208030 NDA Chiesi USA, Inc. 10122-101 10122-101-50 500 mL in 1 BOTTLE, PLASTIC (10122-101-50)
FERRIPROX deferiprone SOLUTION;ORAL 208030 NDA ApoPharma USA, Inc. 52609-4502 52609-4502-7 500 mL in 1 BOTTLE, PLASTIC (52609-4502-7)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;ORALStrength100MG/ML
Approval Date:Sep 9, 2015TE:RLD:Yes
Regulatory Exclusivity Expiration:Apr 30, 2024
Regulatory Exclusivity Use:TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUE TO SICKLE CELL DISEASE OR OTHER ANEMIAS
Patent:⤷  Free Forever TrialPatent Expiration:Jun 28, 2021Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF TREATING TRANSFUSIONAL IRON OVERLOAD
Patent:⤷  Free Forever TrialPatent Expiration:Oct 26, 2029Product Flag?YSubstance Flag?Delist Request?
Patented Use:METHOD OF TREATING TRANSFUSIONAL IRON OVERLOAD

Expired US Patents for NDA 208030

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Chiesi FERRIPROX deferiprone SOLUTION;ORAL 208030-002 Apr 20, 2018 ⤷  Free Forever Trial ⤷  Free Forever Trial
Chiesi FERRIPROX deferiprone SOLUTION;ORAL 208030-001 Sep 9, 2015 ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Merck
Boehringer Ingelheim
Moodys
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.